{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,2]],"date-time":"2026-10-02T17:53:47Z","timestamp":1790963627182,"version":"4.1.0"},"reference-count":47,"publisher":"BMJ","issue":"1","license":[{"start":{"date-parts":[[2019,10,24]],"date-time":"2019-10-24T00:00:00Z","timestamp":1571875200000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["j. immunotherapy cancer"],"published-print":{"date-parts":[[2019,12]]},"DOI":"10.1186\/s40425-019-0762-2","type":"journal-article","created":{"date-parts":[[2019,10,25]],"date-time":"2019-10-25T17:11:11Z","timestamp":1572023471000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":142,"title":["Systemic and local immunity following adoptive transfer of NY-ESO-1 SPEAR T cells in synovial sarcoma"],"prefix":"10.1136","volume":"7","author":[{"given":"Indu","family":"Ramachandran","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniel E.","family":"Lowther","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rebecca","family":"Dryer-Minnerly","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ruoxi","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Svetlana","family":"Fayngerts","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniel","family":"Nunez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gareth","family":"Betts","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Natalie","family":"Bath","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alex J.","family":"Tipping","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Luca","family":"Melchiori","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jean-Marc","family":"Navenot","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John","family":"Glod","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Crystal L.","family":"Mackall","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sandra P.","family":"D\u2019Angelo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dejka M.","family":"Araujo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Warren A.","family":"Chow","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"George D.","family":"Demetri","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mihaela","family":"Druta","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Brian A.","family":"Van Tine","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stephan A.","family":"Grupp","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Albiruni R.","family":"Abdul Razak","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Breelyn","family":"Wilky","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Malini","family":"Iyengar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Trupti","family":"Trivedi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Erin Van","family":"Winkle","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Karen","family":"Chagin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rafael","family":"Amado","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gwendolyn K.","family":"Binder","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Samik","family":"Basu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"239","published-online":{"date-parts":[[2019,10,24]]},"reference":[{"issue":"6","key":"762_CR1","doi-asserted-by":"publisher","first-page":"369","DOI":"10.1016\/j.anndiagpath.2014.09.002","volume":"18","author":"K Thway","year":"2014","unstructured":"Thway K, Fisher C. Synovial sarcoma: defining features and diagnostic evolution. Ann Diagn Pathol. 2014;18(6):369\u201380.","journal-title":"Ann Diagn Pathol"},{"key":"762_CR2","doi-asserted-by":"publisher","first-page":"24","DOI":"10.1186\/s13569-016-0064-0","volume":"6","author":"L Paoluzzi","year":"2016","unstructured":"Paoluzzi L, Cacavio A, Ghesani M, Karambelkar A, Rapkiewicz A, Weber J, et al. Response to anti-PD1 therapy with nivolumab in metastatic sarcomas. Clin Sarcoma Res. 2016;6:24.","journal-title":"Clin Sarcoma Res"},{"issue":"11","key":"762_CR3","doi-asserted-by":"publisher","first-page":"1493","DOI":"10.1016\/S1470-2045(17)30624-1","volume":"18","author":"HA Tawbi","year":"2017","unstructured":"Tawbi HA, Burgess M, Bolejack V, Van Tine BA, Schuetze SM, Hu J, et al. Pembrolizumab in advanced soft-tissue sarcoma and bone sarcoma (SARC028): a multicentre, two-cohort, single-arm, open-label, phase 2 trial. Lancet Oncol. 2017;18(11):1493\u2013501.","journal-title":"Lancet Oncol"},{"issue":"1","key":"762_CR4","doi-asserted-by":"publisher","first-page":"93","DOI":"10.1001\/jamaoncol.2017.1617","volume":"4","author":"M Toulmonde","year":"2018","unstructured":"Toulmonde M, Penel N, Adam J, Chevreau C, Blay JY, Le Cesne A, et al. Use of PD-1 targeting, macrophage infiltration, and IDO pathway activation in sarcomas: a phase 2 clinical trial. JAMA Oncol. 2018;4(1):93\u20137.","journal-title":"JAMA Oncol"},{"issue":"7","key":"762_CR5","doi-asserted-by":"publisher","first-page":"633","DOI":"10.1200\/JCO.2017.75.3384","volume":"36","author":"H Rizvi","year":"2018","unstructured":"Rizvi H, Sanchez-Vega F, La K, Chatila W, Jonsson P, Halpenny D, et al. Molecular determinants of response to anti-programmed cell death (PD)-1 and anti-programmed death-ligand 1 (PD-L1) blockade in patients with non-small-cell lung cancer profiled with targeted next-generation sequencing. J Clin Oncol. 2018;36(7):633\u201341.","journal-title":"J Clin Oncol"},{"issue":"10","key":"762_CR6","doi-asserted-by":"publisher","first-page":"3043","DOI":"10.1111\/cas.13769","volume":"109","author":"N Oike","year":"2018","unstructured":"Oike N, Kawashima H, Ogose A, Hotta T, Hatano H, Ariizumi T, et al. Prognostic impact of the tumor immune microenvironment in synovial sarcoma. Cancer Sci. 2018;109(10):3043\u201354.","journal-title":"Cancer Sci"},{"issue":"17","key":"762_CR7","doi-asserted-by":"publisher","first-page":"3291","DOI":"10.1002\/cncr.30726","volume":"123","author":"SM Pollack","year":"2017","unstructured":"Pollack SM, He Q, Yearley JH, Emerson R, Vignali M, Zhang Y, et al. T-cell infiltration and clonality correlate with programmed cell death protein 1 and programmed death-ligand 1 expression in patients with soft tissue sarcomas. Cancer. 2017;123(17):3291\u2013304.","journal-title":"Cancer"},{"key":"762_CR8","unstructured":"Services USDoHaH. The Cancer Genome Atlas 2017 [Available from: https:\/\/cancergenome.nih.gov\/ ."},{"issue":"6","key":"762_CR9","doi-asserted-by":"publisher","first-page":"856","DOI":"10.1002\/ijc.1282","volume":"92","author":"AA Jungbluth","year":"2001","unstructured":"Jungbluth AA, Chen YT, Stockert E, Busam KJ, Kolb D, Iversen K, et al. Immunohistochemical analysis of NY-ESO-1 antigen expression in normal and malignant human tissues. Int J Cancer. 2001;92(6):856\u201360.","journal-title":"Int J Cancer"},{"issue":"6","key":"762_CR10","doi-asserted-by":"publisher","first-page":"854","DOI":"10.1038\/modpathol.2012.31","volume":"25","author":"JP Lai","year":"2012","unstructured":"Lai JP, Robbins PF, Raffeld M, Aung PP, Tsokos M, Rosenberg SA, et al. NY-ESO-1 expression in synovial sarcoma and other mesenchymal tumors: significance for NY-ESO-1-based targeted therapy and differential diagnosis. Mod Pathol. 2012;25(6):854\u20138.","journal-title":"Mod Pathol"},{"issue":"6","key":"762_CR11","doi-asserted-by":"publisher","first-page":"775","DOI":"10.1097\/01.LAB.0000017169.26718.5F","volume":"82","author":"AP Satie","year":"2002","unstructured":"Satie AP, Rajpert-De Meyts E, Spagnoli GC, Henno S, Olivo L, Jacobsen GK, et al. The cancer-testis gene, NY-ESO-1, is expressed in normal fetal and adult testes and in spermatocytic seminomas and testicular carcinoma in situ. Lab Investig. 2002;82(6):775\u201380.","journal-title":"Lab Investig"},{"issue":"2","key":"762_CR12","doi-asserted-by":"publisher","first-page":"125","DOI":"10.1200\/JCO.2017.75.1610","volume":"36","author":"SM Pollack","year":"2018","unstructured":"Pollack SM, Ingham M, Spraker MB, Schwartz GK. Emerging targeted and immune-based therapies in sarcoma. J Clin Oncol. 2018;36(2):125\u201335.","journal-title":"J Clin Oncol"},{"issue":"7","key":"762_CR13","doi-asserted-by":"publisher","first-page":"917","DOI":"10.1200\/JCO.2010.32.2537","volume":"29","author":"PF Robbins","year":"2011","unstructured":"Robbins PF, Morgan RA, Feldman SA, Yang JC, Sherry RM, Dudley ME, et al. Tumor regression in patients with metastatic synovial cell sarcoma and melanoma using genetically engineered lymphocytes reactive with NY-ESO-1. J Clin Oncol. 2011;29(7):917\u201324.","journal-title":"J Clin Oncol"},{"issue":"8","key":"762_CR14","doi-asserted-by":"publisher","first-page":"944","DOI":"10.1158\/2159-8290.CD-17-1417","volume":"8","author":"SP D'Angelo","year":"2018","unstructured":"D'Angelo SP, Melchiori L, Merchant MS, Bernstein D, Glod J, Kaplan R, et al. Antitumor activity associated with prolonged persistence of adoptively transferred NY-ESO-1 (c259) T cells in synovial sarcoma. Cancer Discov. 2018;8(8):944\u201357.","journal-title":"Cancer Discov"},{"issue":"8","key":"762_CR15","doi-asserted-by":"publisher","first-page":"914","DOI":"10.1038\/nm.3910","volume":"21","author":"AP Rapoport","year":"2015","unstructured":"Rapoport AP, Stadtmauer EA, Binder-Scholl GK, Goloubeva O, Vogl DT, Lacey SF, et al. NY-ESO-1-specific TCR-engineered T cells mediate sustained antigen-specific antitumor effects in myeloma. Nat Med. 2015;21(8):914\u201321.","journal-title":"Nat Med"},{"key":"762_CR16","doi-asserted-by":"publisher","first-page":"42","DOI":"10.1186\/s40425-015-0088-7","volume":"3","author":"A Cesano","year":"2015","unstructured":"Cesano A. nCounter((R)) PanCancer immune profiling panel (NanoString Technologies, Inc., Seattle, WA). J Immunother Cancer. 2015;3:42.","journal-title":"J Immunother Cancer"},{"key":"762_CR17","unstructured":"The R project for statistical computing. Vienna: The R Foundation; 2018 [Available from: https:\/\/www.r-project.org\/ ."},{"key":"762_CR18","doi-asserted-by":"publisher","first-page":"130","DOI":"10.1016\/j.humpath.2016.12.006","volume":"61","author":"K Iura","year":"2017","unstructured":"Iura K, Maekawa A, Kohashi K, Ishii T, Bekki H, Otsuka H, et al. Cancer-testis antigen expression in synovial sarcoma: NY-ESO-1, PRAME, MAGEA4, and MAGEA1. Hum Pathol. 2017;61:130\u20139.","journal-title":"Hum Pathol"},{"issue":"224","key":"762_CR19","doi-asserted-by":"publisher","first-page":"224ra25","DOI":"10.1126\/scitranslmed.3008226","volume":"6","author":"ML Davila","year":"2014","unstructured":"Davila ML, Riviere I, Wang X, Bartido S, Park J, Curran K, et al. Efficacy and toxicity management of 19-28z CAR T cell therapy in B cell acute lymphoblastic leukemia. Sci Transl Med. 2014;6(224):224ra25.","journal-title":"Sci Transl Med"},{"issue":"6","key":"762_CR20","doi-asserted-by":"publisher","first-page":"540","DOI":"10.1200\/JCO.2014.56.2025","volume":"33","author":"JN Kochenderfer","year":"2015","unstructured":"Kochenderfer JN, Dudley ME, Kassim SH, Somerville RP, Carpenter RO, Stetler-Stevenson M, et al. Chemotherapy-refractory diffuse large B-cell lymphoma and indolent B-cell malignancies can be effectively treated with autologous T cells expressing an anti-CD19 chimeric antigen receptor. J Clin Oncol. 2015;33(6):540\u20139.","journal-title":"J Clin Oncol"},{"issue":"9967","key":"762_CR21","doi-asserted-by":"publisher","first-page":"517","DOI":"10.1016\/S0140-6736(14)61403-3","volume":"385","author":"DW Lee","year":"2015","unstructured":"Lee DW, Kochenderfer JN, Stetler-Stevenson M, Cui YK, Delbrook C, Feldman SA, et al. T cells expressing CD19 chimeric antigen receptors for acute lymphoblastic leukaemia in children and young adults: a phase 1 dose-escalation trial. Lancet. 2015;385(9967):517\u201328.","journal-title":"Lancet"},{"issue":"16","key":"762_CR22","doi-asserted-by":"publisher","first-page":"1507","DOI":"10.1056\/NEJMoa1407222","volume":"371","author":"SL Maude","year":"2014","unstructured":"Maude SL, Frey N, Shaw PA, Aplenc R, Barrett DM, Bunin NJ, et al. Chimeric antigen receptor T cells for sustained remissions in leukemia. N Engl J Med. 2014;371(16):1507\u201317.","journal-title":"N Engl J Med"},{"issue":"6","key":"762_CR23","doi-asserted-by":"publisher","first-page":"2123","DOI":"10.1172\/JCI85309","volume":"126","author":"CJ Turtle","year":"2016","unstructured":"Turtle CJ, Hanafi LA, Berger C, Gooley TA, Cherian S, Hudecek M, et al. CD19 CAR-T cells of defined CD4+:CD8+ composition in adult B cell ALL patients. J Clin Invest. 2016;126(6):2123\u201338.","journal-title":"J Clin Invest"},{"issue":"355","key":"762_CR24","doi-asserted-by":"publisher","first-page":"355ra116","DOI":"10.1126\/scitranslmed.aaf8621","volume":"8","author":"CJ Turtle","year":"2016","unstructured":"Turtle CJ, Hanafi LA, Berger C, Hudecek M, Pender B, Robinson E, et al. Immunotherapy of non-Hodgkin\u2019s lymphoma with a defined ratio of CD8+ and CD4+ CD19-specific chimeric antigen receptor-modified T cells. Sci Transl Med. 2016;8(355):355ra116.","journal-title":"Sci Transl Med"},{"issue":"5","key":"762_CR25","doi-asserted-by":"publisher","first-page":"439","DOI":"10.1056\/NEJMoa1709866","volume":"378","author":"SL Maude","year":"2018","unstructured":"Maude SL, Laetsch TW, Buechner J, Rives S, Boyer M, Bittencourt H, et al. Tisagenlecleucel in children and young adults with B-cell lymphoblastic leukemia. N Engl J Med. 2018;378(5):439\u201348.","journal-title":"N Engl J Med"},{"key":"762_CR26","doi-asserted-by":"crossref","unstructured":"Berdeja JG, Lin Y, Raje N, Munshi N, Siegel D, Liedtke M, et al. Durable clinical responses in heavily pretreated patients with relapsed\/refractory multiple myeloma: updated results from a multicenter study of bb2121 Anti-Bcma CAR T cell therapy. NEJM. 2017;130(Suppl 1):740.","DOI":"10.1182\/blood.V130.Suppl_1.740.740"},{"issue":"6286","key":"762_CR27","doi-asserted-by":"publisher","first-page":"658","DOI":"10.1126\/science.aaf2834","volume":"352","author":"CU Blank","year":"2016","unstructured":"Blank CU, Haanen JB, Ribas A, Schumacher TN. CANCER IMMUNOLOGY. The \u201ccancer immunogram\u201d. Science. 2016;352(6286):658\u201360.","journal-title":"Science"},{"issue":"6","key":"762_CR28","doi-asserted-by":"publisher","first-page":"1128","DOI":"10.1016\/j.ccell.2018.05.002","volume":"33","author":"MJ McBride","year":"2018","unstructured":"McBride MJ, Pulice JL, Beird HC, Ingram DR, D\u2019Avino AR, Shern JF, et al. The SS18-SSX fusion oncoprotein hijacks BAF complex targeting and function to drive synovial sarcoma. Cancer Cell. 2018;33(6):1128\u201341.e7.","journal-title":"Cancer Cell"},{"issue":"3","key":"762_CR29","doi-asserted-by":"publisher","first-page":"176","DOI":"10.1038\/s41434-018-0019-6","volume":"25","author":"KL Lowe","year":"2018","unstructured":"Lowe KL, Mackall CL, Norry E, Amado R, Jakobsen BK, Binder G. Fludarabine and neurotoxicity in engineered T-cell therapy. Gene Ther. 2018;25(3):176\u201391.","journal-title":"Gene Ther"},{"issue":"7709","key":"762_CR30","doi-asserted-by":"publisher","first-page":"307","DOI":"10.1038\/s41586-018-0178-z","volume":"558","author":"JA Fraietta","year":"2018","unstructured":"Fraietta JA, Nobles CL, Sammons MA, Lundh S, Carty SA, Reich TJ, et al. Disruption of TET2 promotes the therapeutic efficacy of CD19-targeted T cells. Nature. 2018;558(7709):307\u201312.","journal-title":"Nature"},{"issue":"9","key":"762_CR31","doi-asserted-by":"publisher","first-page":"2214","DOI":"10.1016\/j.ymthe.2017.05.012","volume":"25","author":"A Heczey","year":"2017","unstructured":"Heczey A, Louis CU, Savoldo B, Dakhova O, Durett A, Grilley B, et al. CAR T cells administered in combination with Lymphodepletion and PD-1 inhibition to patients with neuroblastoma. Mol Ther. 2017;25(9):2214\u201324.","journal-title":"Mol Ther"},{"issue":"16","key":"762_CR32","doi-asserted-by":"publisher","first-page":"1803","DOI":"10.1200\/JCO.2016.71.3024","volume":"35","author":"JN Kochenderfer","year":"2017","unstructured":"Kochenderfer JN, Somerville RPT, Lu T, Shi V, Bot A, Rossi J, et al. Lymphoma remissions caused by anti-CD19 chimeric antigen receptor T cells are associated with high serum Interleukin-15 levels. J Clin Oncol. 2017;35(16):1803\u201313.","journal-title":"J Clin Oncol"},{"issue":"9","key":"762_CR33","doi-asserted-by":"publisher","first-page":"1299","DOI":"10.1007\/s00262-011-1037-z","volume":"60","author":"L Bao","year":"2011","unstructured":"Bao L, Dunham K, Lucas K. MAGE-A1, MAGE-A3, and NY-ESO-1 can be upregulated on neuroblastoma cells to facilitate cytotoxic T lymphocyte-mediated tumor cell killing. Cancer Immunol Immunother. 2011;60(9):1299\u2013307.","journal-title":"Cancer Immunol Immunother"},{"issue":"5","key":"762_CR34","doi-asserted-by":"publisher","first-page":"1019","DOI":"10.1158\/1078-0432.CCR-17-1792","volume":"24","author":"EA Griffiths","year":"2018","unstructured":"Griffiths EA, Srivastava P, Matsuzaki J, Brumberger Z, Wang ES, Kocent J, et al. NY-ESO-1 vaccination in combination with decitabine induces antigen-specific T-lymphocyte responses in patients with myelodysplastic syndrome. Clin Cancer Res. 2018;24(5):1019\u201329.","journal-title":"Clin Cancer Res"},{"issue":"10","key":"762_CR35","doi-asserted-by":"publisher","first-page":"e0139221","DOI":"10.1371\/journal.pone.0139221","volume":"10","author":"AS Klar","year":"2015","unstructured":"Klar AS, Gopinadh J, Kleber S, Wadle A, Renner C. Treatment with 5-Aza-2\u2032-Deoxycytidine induces expression of NY-ESO-1 and facilitates cytotoxic T lymphocyte-mediated tumor cell killing. PLoS One. 2015;10(10):e0139221.","journal-title":"PLoS One"},{"key":"762_CR36","doi-asserted-by":"publisher","first-page":"947","DOI":"10.3389\/fimmu.2018.00947","volume":"9","author":"R Thomas","year":"2018","unstructured":"Thomas R, Al-Khadairi G, Roelands J, Hendrickx W, Dermime S, Bedognetti D, et al. NY-ESO-1 based immunotherapy of cancer: current perspectives. Front Immunol. 2018;9:947.","journal-title":"Front Immunol"},{"issue":"16","key":"762_CR37","doi-asserted-by":"publisher","first-page":"1509","DOI":"10.1056\/NEJMoa1215134","volume":"368","author":"SA Grupp","year":"2013","unstructured":"Grupp SA, Kalos M, Barrett D, Aplenc R, Porter DL, Rheingold SR, et al. Chimeric antigen receptor-modified T cells for acute lymphoid leukemia. N Engl J Med. 2013;368(16):1509\u201318.","journal-title":"N Engl J Med"},{"issue":"20","key":"762_CR38","doi-asserted-by":"publisher","first-page":"2406","DOI":"10.1182\/blood-2015-08-665547","volume":"127","author":"R Gardner","year":"2016","unstructured":"Gardner R, Wu D, Cherian S, Fang M, Hanafi LA, Finney O, et al. Acquisition of a CD19-negative myeloid phenotype allows immune escape of MLL-rearranged B-ALL from CD19 CAR-T-cell therapy. Blood. 2016;127(20):2406\u201310.","journal-title":"Blood"},{"issue":"399","key":"762_CR39","doi-asserted-by":"publisher","first-page":"eaaa0984","DOI":"10.1126\/scitranslmed.aaa0984","volume":"9","author":"Donald M. O\u2019Rourke","year":"2017","unstructured":"O'Rourke DM, Nasrallah MP, Desai A, Melenhorst JJ, Mansfield K, Morrissette JJD, et al. A single dose of peripherally infused EGFRvIII-directed CAR T cells mediates antigen loss and induces adaptive resistance in patients with recurrent glioblastoma. Sci Transl Med. 2017;9(399). https:\/\/doi.org\/10.1126\/scitranslmed.aaa0984 .","journal-title":"Science Translational Medicine"},{"issue":"450","key":"762_CR40","doi-asserted-by":"publisher","first-page":"eaar3342","DOI":"10.1126\/scitranslmed.aar3342","volume":"10","author":"Scott J. Rodig","year":"2018","unstructured":"Rodig SJ, Gusenleitner D, Jackson DG, Gjini E, Giobbie-Hurder A, Jin C, et al. MHC proteins confer differential sensitivity to CTLA-4 and PD-1 blockade in untreated metastatic melanoma. Sci Transl Med. 2018;10(450). https:\/\/doi.org\/10.1126\/scitranslmed.aar3342 .","journal-title":"Science Translational Medicine"},{"issue":"1","key":"762_CR41","doi-asserted-by":"publisher","first-page":"1136","DOI":"10.1038\/s41467-017-01062-w","volume":"8","author":"M Sade-Feldman","year":"2017","unstructured":"Sade-Feldman M, Jiao YJ, Chen JH, Rooney MS, Barzily-Rokni M, Eliane JP, et al. Resistance to checkpoint blockade therapy through inactivation of antigen presentation. Nat Commun. 2017;8(1):1136.","journal-title":"Nat Commun"},{"issue":"6","key":"762_CR42","doi-asserted-by":"publisher","first-page":"1259","DOI":"10.1016\/j.cell.2017.10.001","volume":"171","author":"N McGranahan","year":"2017","unstructured":"McGranahan N, Rosenthal R, Hiley CT, Rowan AJ, Watkins TBK, Wilson GA, et al. Allele-specific HLA loss and immune escape in lung cancer evolution. Cell. 2017;171(6):1259\u201371.e11.","journal-title":"Cell"},{"issue":"1","key":"762_CR43","doi-asserted-by":"publisher","first-page":"3868","DOI":"10.1038\/s41467-018-06300-3","volume":"9","author":"KG Paulson","year":"2018","unstructured":"Paulson KG, Voillet V, McAfee MS, Hunter DS, Wagener FD, Perdicchio M, et al. Acquired cancer resistance to combination immunotherapy from transcriptional loss of class I HLA. Nat Commun. 2018;9(1):3868.","journal-title":"Nat Commun"},{"issue":"6382","key":"762_CR44","doi-asserted-by":"publisher","first-page":"1350","DOI":"10.1126\/science.aar4060","volume":"359","author":"A Ribas","year":"2018","unstructured":"Ribas A, Wolchok JD. Cancer immunotherapy using checkpoint blockade. Science. 2018;359(6382):1350\u20135.","journal-title":"Science"},{"issue":"1","key":"762_CR45","doi-asserted-by":"publisher","first-page":"11158","DOI":"10.1038\/s41598-018-28944-3","volume":"8","author":"H Halse","year":"2018","unstructured":"Halse H, Colebatch AJ, Petrone P, Henderson MA, Mills JK, Snow H, et al. Multiplex immunohistochemistry accurately defines the immune context of metastatic melanoma. Sci Rep. 2018;8(1):11158.","journal-title":"Sci Rep"},{"key":"762_CR46","doi-asserted-by":"publisher","first-page":"86","DOI":"10.3389\/fimmu.2017.00086","volume":"8","author":"LA Elliott","year":"2017","unstructured":"Elliott LA, Doherty GA, Sheahan K, Ryan EJ. Human tumor-infiltrating myeloid cells: phenotypic and functional diversity. Front Immunol. 2017;8:86.","journal-title":"Front Immunol"},{"issue":"1","key":"762_CR47","doi-asserted-by":"publisher","first-page":"49","DOI":"10.1016\/j.immuni.2014.06.010","volume":"41","author":"R Noy","year":"2014","unstructured":"Noy R, Pollard JW. Tumor-associated macrophages: from mechanisms to therapy. Immunity. 2014;41(1):49\u201361.","journal-title":"Immunity"}],"container-title":["Journal for ImmunoTherapy of Cancer"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s40425-019-0762-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1186\/s40425-019-0762-2\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s40425-019-0762-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,10,2]],"date-time":"2022-10-02T17:01:41Z","timestamp":1664730101000},"score":1,"resource":{"primary":{"URL":"https:\/\/jitc.bmj.com\/lookup\/doi\/10.1186\/s40425-019-0762-2"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,10,24]]},"references-count":47,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2019,12]]}},"alternative-id":["762"],"URL":"https:\/\/doi.org\/10.1186\/s40425-019-0762-2","relation":{},"ISSN":["2051-1426"],"issn-type":[{"value":"2051-1426","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,10,24]]},"assertion":[{"value":"9 May 2019","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"26 September 2019","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"24 October 2019","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"This study (NCT01343043) was conducted in compliance with the Declaration of Helsinki, and in accordance with local legal and regulatory requirements. The protocol was approved by each center\u2019s Institutional Review Board, and informed consent forms were obtained for all patients.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"All authors of the manuscript have read and agreed to its content and are accountable for all aspects of the accuracy and integrity of the manuscript. The manuscript is original, has not already been published, and is not currently under consideration by another journal.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"IR, DEL, RDM, RW, SF, DN, GB, NB, AJT, LM, JMN, MI, TT, EVW, KC, RA, GKB, and SB: employees of Adaptimmune and have stock or other ownership interests in Adaptimmune.JG: NoneCLM: Consulting for Adaptimmune, GlaxoSmithKline, Allogene, Nektar, Vor, PACT, Unum, Bryologyx, Apricity, Roche, Lyell. Equity in Allogene, Vor, PACT, Unum, Lyell. Research Funding from: Obsidian.SPD: Consulting for Amgen, EMD Serono, Nektar, travel support from AdaptimmuneDMA: NoneWAC: Speaker\u2019s bureau and research funding from Novartis, data safety monitoring board for AdvenchenGDD: NoneBAVT: Basic science grant funding from Pfizer, Tracon, and Merck; consulting fees from Epizyme, Lilly, CytRX, Janssen, Immune Design, Daiichi Sankyo, Plexxicon and Adaptimmune; speaking fees from Caris, Janseen, and LillyMD: Consulting and speaker\u2019s bureau for Eisai and LillySG: Research and\/or clinical trial support from Novartis, Servier, Adaptimmune, and Kite. Consulting, study steering committees, or scientific advisory boards: Novartis, Cellectis, Adaptimmune, Eureka, TCR2, Juno, GlaxoSmithKline, Vertex, Cure Genetics, Humanigen, and Roche.ARAR: Consulting for Lilly, Merck, Boehringer Ingelheim, research funding from CASI Pharmaceuticals, Boehringer IngelheimBW: Research support from Merck, Pfizer, Agenus, and consulting for Lilly and Immune Design","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"276"}}